Edit
MP Healthcare Venture Management
https://www.mp-healthcare.comLast activity: 06.10.2025
Active
Helping entrepreneurs build tomorrow’s life science companies.
Employees: 1-10
Portfolio 18
| Date | Name | Website | Total Raised | Location |
| 07.05.2025 | Draupnir B... | draupnir.bio | $13.13M | Denmark, C... |
| 22.06.2023 | PharmEnabl... | pharmenable.com | $9.99M | United Kin... |
| 07.10.2021 | Sola | sola-bio.com | - | - |
| 20.07.2021 | EditForce ... | editforce.co.jp | - | - |
| - | Ribometrix... | ribometrix.com | $45.3M | United Sta... |
| - | QurAlis | quralis.com | $135.5M | United Sta... |
| - | MyCartis | mycartis.net | - | Belgium, E... |
| - | Corporate ... | miragentherapeutics.com | $49.5M | - |
| - | Blacksmith... | blacksmithmedicines.com | $3.3M | - |
| - | Korro Bio,... | korrobio.com | $207.5M | United Sta... |
Show more
News 80
Show more
Mentions in press and media 15
| Date | Title | Description |
| 30.05.2025 | GlycoEra AG: Pioneering a New Era in Autoimmune Disease Treatment | In the world of biotechnology, innovation is the lifeblood that fuels progress. GlycoEra AG is a shining example of this principle. Recently, the company secured $130 million in funding to advance its groundbreaking therapies for autoimmune... |
| 27.05.2025 | GlycoEra AG raises $130 Million to advance therapies for autoimmune diseases | GlycoEra’s proprietary platform enables the development of best-in-class degraders that target a broad spectrum of extracellular proteins. GlycoEra’s degraders are bispecific molecules that leverage a naturally occurring process to degrade... |
| 05.03.2025 | TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases | Cambridge, UK, 05 March 2025: TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, today announced the closing of its $31 million (£25 million) seed funding ... |
| 10.11.2015 | Daily funding roundup - November 10, 2015 Early-Stage Venture-Capital Investors Early-Stage Venture-Capital Investors | Careem secured $60M; Transfix raised $12M; Spiro closed $1.5M Trucking remains the most widely used way of shipping goods, with heavy duty semi-trucks being responsible for shipping 70% of all U.S. freight.. But it's also an industry that h... |
| 24.03.2014 | Emerging sources of early-stage life science funding embrace the role of ‘venture catalysts’ | “The biggest challenge for the pharmaceutical company is actually coming up with a product that works,” said Jeffrey Moore, managing partner of Healthcare Venture Management. So other factors like a startup’s executive team become less impo... |
| 09.12.2013 | Covagen Secures CHF 42 Million in Series B Financing | |
| 25.10.2012 | Thrasos Therapeutics Completes $35M Financing | Thrasos Therapeutics, a Montreal, QC, Canada-based clinical stage, biotherapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease, has completed a $35m financing. Th... |
| 20.02.2012 | Are new life science investors eyeing Research Triangle Park? | Plus, the recent CED Life Science Conference had a series of new investor faces in the audience, as well as some prodigal sons. A few I spoke with said they were there because they thought there were deals to be done that the typical Park i... |
| 05.01.2012 | Syndexa Pharmaceuticals Raises Series B1 funding from MP Healthcare Venture Management | Syndexa Pharmaceuticals Corp., a Watertown, MA-based biopharmaceutical company developing drugs to treat metabolic diseases, has raised additional Series B1 funding from MP Healthcare Venture Management (MPH). This investment brings the tot... |
| 05.01.2012 | Syndexa Pharma Expands Series B1 Round | WATERTOWN, MA, Biopharmaceutical company developing first-in-class drugs to treat metabolic diseases, announced that it has secured additional Series B1 financing from MP Healthcare Venture Management (MPH) >> Click here for more f... |
Show more